Daewoong Pharmaceutical signs co-promotion agreement of ‘Foxiga & Xigduo’ with AstraZeneca

Published: 2018-03-26 10:29:15

Updated: 2018-03-26 10:29:15

Daewoong Pharmaceutical(CEO Jong-Wook Lee) signed a co-promotional partnership agreement of ‘Forxiga(dapagliflozin)’ and ‘Xigduo(dapagliflozin+metformin),’ SGLT-2 inhibitors for the treatment of type 2 diabetes with AstraXeneca Korea(CEO Sang-Pyo Kim).

The agreement has taken a progress to extend the original agreement to co-promotion. Established on the last 1^st of March, the original only co...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.